Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma

Cancer. 2005 Jun 15;103(12):2435-46. doi: 10.1002/cncr.21123.


Substantial effort has focused on the development of novel targeted agents for treating patients with late-stage colorectal carcinoma. These agents are designed specifically to inhibit biochemical processes associated with pathogenesis. Numerous molecules targeting the epidermal growth factor receptor have been investigated as therapeutic agents and appear to herald a shift in the treatment paradigm for colorectal carcinoma.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Colorectal Neoplasms / drug therapy*
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / physiology
  • Humans
  • Signal Transduction


  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • ErbB Receptors